Aquila Bioscience has developed revolutionary decontamination technology that helps protect people from dangerous pathogens and other viral infections like coronavirus. We are delighted to receive funding from EIC which allows us to substantially scale up production and deliver this technology more quickly to frontline and other workers in Ireland and across the globe. This technology will make it safer for people to return to work and help get Ireland’s economy moving again.
Aquila Bioscience have been successfully registered as a foreign manufacturing facility with FDA under Owner/ Operator Number 10074735
The ABD Wipe product is registered with FDA under device listing D405606.
Aquila Bioscience are now permitted to market and sell the ABD Device in the US market.
At the 13th CBRNe Protection Symposium in Malmoe (Sweden) ABD Technology was described to leading scientists, industries and end-users during a presentation ‘Biothreat Agent Protection: Novel approaches for capture, detection and decontamination’ (Session 4 – Hazard Management). For further information, please check out the meeting website here: https://cbw.se/home
Charlotte Dessaux, a French PhD student (ESR 4 in PathSense ITN), working at the Spanish National Centre for Biotechnology (CNB-CSIC) under supervision of Prof. Francisco Garcia del Portillo in Madrid (Spain), recently came to Galway for a month-long secondment in Aquila Bioscience to investigate bacterial glycan-lectin interactions in foodborne pathogens and to experience start-up SME environment. Charlotte presented her research at the 20th International Symposium on Problems of Listeria and Listeriosis (ISOPOL 2019) in Toronto, Canada. For further information, please check out the abstract submitted to ISOPOL 2019 under this link